Due to ‘overwhelming demand,’ Sanofi and AstraZeneca’s RSV antibody to be in limited supply 

Sanofi is ex­pect­ing sup­ply con­straints of its in­fant RSV an­ti­body Bey­for­tus, which it co-de­vel­oped with As­traZeneca, in the first quar­ter of this year. While it is ex­pect­ing to boost pro­duc­tion, the com­pa­ny says it’s too ear­ly to say by how much.

The French phar­ma is work­ing to lift any man­u­fac­tur­ing bot­tle­necks and “un­lock ca­pac­i­ty” to tack­le sup­ply con­straints, but “the ques­tion is how much progress we can make in 2024,” CEO Paul Hud­son not­ed on a me­dia call Thurs­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.